Sixmo – A Long-Acting Implant for Opioid Dependence
What Is Sixmo? Sixmo is a buprenorphine hydrochloride implant designed as a long-lasting substitution treatment for opioid dependence. It is intended for clinically stable adult patients requiring a daily dose of no more than 8 mg of sublingual buprenorphine. The implant must be used alongside comprehensive medical, social, and psychological support.European Medicines Agency (EMA)European Pharmaceutical […]
Fluenz Tetra live attenuated quadrivalent influenza vaccine— A Comprehensive Overview
What Is Fluenz Tetra? Fluenz Tetra is a live attenuated quadrivalent influenza vaccine, administered intranasally as a needle-free spray. It protects against four influenza virus strains—two A types (H1N1 and H3N2) and two B types. This broader formulation offers enhanced protection compared to traditional trivalent vaccines.MedPath+1Wikipedia Originally approved by the European Commission on 4 December […]
EMA Confirms Suicidal Thoughts with Finasteride — Detailed summary, implications, and a practical pharmacovigilance / manufacturer action plan
Source documents: EMA PRAC communications and referral page (May–June 2025). European Medicines Agency (EMA)+1 Executive summary — the one-minute version What PRAC found (evidence & conclusions) Key regulatory changes and public health measures Clinical and public-health implications (who should worry and what to do) Impact on manufacturers — regulatory & operational checklist Manufacturers (brand and […]
EMA’s Update on Azithromycin Use — May 23, 2025
Key Regulatory Shift The European Medicines Agency’s (EMA) CHMP recommended updating the approved uses of azithromycin (oral and IV) to combat rising antimicrobial resistance (AMR)—particularly given its designation in WHO’s Watch category, which flags antibiotics at higher risk of driving resistance. (turn0search0) What’s Changed? Refined and Harmonized Indications Approvals have been narrowed and standardized, covering […]
Philips Respironics BiPAP A30 / A40 / V30 — Continuous Ventilator Correction, Clinical Risks, and Manufacturer Action Plan
Source: FDA Medical Device Recalls page (updated Aug 6, 2025).Link reviewed: FDA recall notice for Philips Respironics update of use instructions for BiPAP A30, A40, and V30 due to interruptions and/or loss of therapy. U.S. Food and Drug Administration Executive summary Philips Respironics issued an urgent device correction for all lots of the BiPAP A30, […]
Early Alert: Boston Scientific ENDOTAK RELIANCE Defibrillation Leads — investigative report, clinical guidance, and manufacturer action plan
Source: FDA Early Alert (posted Aug 6, 2025). U.S. Food and Drug Administration Executive summary (two sentences) The FDA posted an Early Alert after Boston Scientific notified clinicians that certain ENDOTAK RELIANCE defibrillation leads with ePTFE-coated shock coils are showing coil calcification that correlates with a gradual rise in low-voltage shock impedance (LVSI) and can […]
Early Alert: Medline ReNewal Reprocessed EP Catheters with Residual Particulates – What You Need to Know
Date of FDA Page Update: August 6, 2025 U.S. Food and Drug Administration The device and product details These catheters are used for electrophysiology (EP) mapping, stimulation, and recording in diagnosing and managing cardiac arrhythmias via endocardial and intravascular access. U.S. Food and Drug Administration Reason for the Early Alert Medline ReNewal found that affected […]
Max Mobility / Permobil Expands Worldwide Recall of SmartDrive SpeedControl Dial — Investigative report and manufacturer action plan
Published: August 12, 2025Source: Company announcement posted on FDA recalls page. U.S. Food and Drug Administration Executive summary (quick take) Max Mobility / Permobil has announced a voluntary, worldwide expanded recall and market removal of all SpeedControl Dials used with the SmartDrive MX2+ power-assist device. The action covers every SpeedControl Dial manufactured and distributed between […]
FDA lifts pause on IXCHIQ for adults ≥60 and approves new label warnings
What happened—quick timeline Why the concern in the first place? IXCHIQ is a live, attenuated chikungunya vaccine; it can produce chikungunya-like symptoms. FDA’s case review included serious adverse events in older adults, some consistent with severe complications of chikungunya disease (e.g., encephalitis). One death from encephalitis was specifically noted in FDA’s safety communication, and earlier […]